Triple therapy for DME better than one

Article

Triple therapy consisting of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation may facilitate early recovery of vision in patients with intractable diabetic macular oedema.

Triple therapy consisting of vitrectomy, intravitreal triamcinolone and macular laser photocoagulation may facilitate early recovery of vision in patients with intractable diabetic macular oedema (DME). These are the recent findings of a study in the October issue of the American Journal of Ophthalmology.

Twenty-four eyes of 24 subjects diagnosed with intractable DME underwent vitrectomy followed by intravitreal triamcinolone acetonide injection and macular laser photocoagulation at one and 14 days after, respectively. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before surgery and three, six and 12 months postoperatively.

The mean logarithm of the minimum angle of resolution BCVA was 0.88±0.37 before surgery, 0.55±0.33 at three months, 0.56±0.27 at six months and 0.48±0.28 at 12 months. Meanwhile, the mean CMTs before and three, six and 12 months after therapy were 514±187 µm, 253±138 µm, 219±95 µm and 197±91 µm, respectively.

The major adverse events after therapy were development of nuclear sclerotic cataracts (eight of 12 phakic eyes) and elevation of intraocular pressure (eight of 24 eyes).

Based on these results, the authors concluded that the triple therapy may facilitate early recovery of vision and may improve the long-term outcomes in some patients with DME refractory to conventional monotherapy.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.